By Dr. Samar Bursheh
A blood test may now help a specialist determine whether Alzheimer-related changes are present in the brain. Wearable sensors can track not only glucose but ketones as well. Researchers are even designing cancer vaccines around the unique genetic fingerprint of a patient's tumor.
What sounded like science fiction only a few years ago is beginning to enter clinical medicine. The larger shift is even more important: medicine is moving from reacting to disease toward earlier detection, prevention, more precise treatment, and preserving function for longer.
As 2027 approaches, these are six developments worth watching and what patients need to understand about each one.
1. Alzheimer's Disease Is Moving Closer to a Blood Test
The new Alzheimer blood tests can help with diagnosis. They look for patterns of proteins linked to Alzheimer-related changes in the brain, giving doctors a simpler alternative to a PET scan or spinal tap when someone is already having memory or thinking problems (FDA, 2025).
There is an important catch. The test is intended for adults age 50 or older who already have memory or thinking symptoms and are being evaluated for Alzheimer disease, not for healthy people without symptoms. It is one piece of the picture, and the result must be weighed alongside a complete clinical evaluation rather than read in isolation.
2 Menopause Medicine Is Being Rewritten
What changed? In February 2026, the FDA removed the strongest boxed warnings about cardiovascular disease, breast cancer, and probable dementia from an initial group of menopausal hormone therapy products. This does not mean hormone therapy is risk-free. The boxed warning regarding endometrial cancer remains for systemic estrogen-only products used in women who still have a uterus. The change reflects a more individualized, timing-based understanding of who may benefit and how treatment should be selected (FDA, 2026). For healthy women without contraindications, the first 10 years after menopause—or generally before age 60—are often described as a “window of opportunity,” when the benefit-risk balance of hormone therapy is most favorable. This is not an expiration date: women who are older or further from menopause may still be appropriate candidates depending on their symptoms, medical history, treatment goals, and individualized risk assessment.
In my practice, I begin with a comprehensive assessment of symptoms, medical and family history, cardiovascular, breast, and bone health, laboratory results, and personal goals. When hormone therapy is appropriate, I generally favor an individualized regimen using FDA-approved bioidentical estradiol and, for women with a uterus, micronized progesterone.
For women who cannot or prefer not to use hormones, FDA-approved nonhormonal treatments such as fezolinetant and elinzanetant offer additional options. In my practice, I also prescribe testosterone for carefully selected postmenopausal women with distressing hypoactive sexual desire disorder. Although no testosterone formulation is currently FDA-approved specifically for women in the United States, clinical data support its use for this indication at physiologic female doses with appropriate monitoring. The goal is not hormones for everyone or hormones for no one, but precise care for the individual woman (Parish et al., 2021).
At Nutriamed, menopause care extends beyond hormone prescriptions to muscle preservation, nutrition and gut health, vaginal and urinary health, sexual wellness, and the emerging role of the gut and vaginal microbiomes. Proven therapies, including vaginal estrogen or vaginal DHEA when appropriate, remain central, while probiotics and other microbiome-directed therapies are considered thoughtfully as the evidence evolves.
3. The Next Generation of Metabolic Medicine
The more meaningful question is no longer simply, 'How much weight was lost?' We should also ask what happened to blood pressure, glucose, visceral fat, liver health, strength, and lean mass. This is the approach we use in metabolic optimization at Nutriamed: medical treatment is combined with nutrition, body-composition monitoring, laboratory follow-up, and muscle-focused exercise. Losing weight is not enough if a patient is also losing excessive muscle or becoming metabolically weaker.
One drug, three targets. Semaglutide acts on GLP-1, while tirzepatide acts on GLP-1 and GIP. The next step is retatrutide, an investigational triple agonist that also targets the glucagon receptor. GLP-1 helps regulate appetite, GIP supports the insulin response, and glucagon influences energy use. Retatrutide is being studied as a once-weekly treatment for obesity and type 2 diabetes, as well as obesity-related conditions including sleep apnea and knee osteoarthritis (Giblin et al., 2026). In a phase 2 study, the highest dose produced an average weight reduction of approximately 24 percent after 48 weeks (Jastreboff et al., NEJM, 2023).
Retatrutide is still experimental and is not FDA-approved. Its long-term benefits and safety continue to be studied. As with other medications in this family, gastrointestinal effects are common, and preserving muscle through adequate nutrition and resistance training remains essential as weight comes off.
4. Wearables Are Becoming Medical Devices
Wearable technology is moving beyond step counts and sleep scores. Over-the-counter continuous glucose monitors now allow many adults who do not use insulin to see how meals, exercise, sleep, and stress affect their glucose patterns. In selected patients, I use this information to identify patterns and guide metabolic care, but the numbers need clinical context. The next advance will not be simply collecting more data. It will be integrating wearable readings with laboratory results, medications, body composition, and progress over time in one useful clinical record.
In 2026, the FDA also authorized the first wearable system that continuously monitors both glucose and ketones for people with diabetes. This could help identify rising ketones before diabetic ketoacidosis becomes a medical emergency. More information, however, does not automatically create better health. Without interpretation, wearable data can create anxiety, unnecessary restriction, or false reassurance.
5. The Immune System Is Becoming Programmable
Some of the most exciting research in medicine involves teaching the immune system to recognize disease more precisely. Personalized cancer vaccines are created by analyzing an individual tumor, identifying its unique mutations, and training immune cells to target them. Small early trials in kidney and pancreatic cancer have produced encouraging immune responses, although larger studies are needed before these vaccines become routine treatment.
Scientists are also exploring whether CAR T cells, immune cells engineered to attack a specific target, can be created inside the body rather than removed, modified in a laboratory, and returned to the patient. Early laboratory and animal research suggests this might eventually make cell therapy more accessible for certain cancers and autoimmune diseases. It is a remarkable idea, but it remains experimental.
6. Peptides Are Promising but Proof Still Matters
Peptides have become one of the most heavily marketed trends in longevity and recovery. The term itself can be misleading: many established medications, including insulin and several GLP-1 therapies, are peptides. The concern is with unapproved compounds promoted for injury healing, fat loss, muscle growth, sleep, or anti-aging when the claims extend far beyond the available human evidence.
In 2026, FDA advisers considered whether several popular peptides, including BPC-157, TB-500, KPV, and MOTS-c, should be eligible for broader pharmacy compounding. That is not the same as FDA approval. Compounded products do not undergo the FDA's standard premarket review for safety, effectiveness, and manufacturing quality, and the agency has identified limited safety information and potential concerns for several of these substances.
I am interested in the future of peptide medicine, but safety comes first. Before recommending any of these therapies, I want to see meaningful human data, reliable manufacturing, appropriate dosing, and a clear understanding of the risks.
The Most Important Advance
The most important change in medicine may not be any single drug or device. It is the movement toward earlier detection, a greater focus on prevention, and precision medicine that matches treatment more closely to the individual.
For patients, this is exciting, but it also requires judgment. Before pursuing a new therapy, ask whether it is approved, what evidence supports it, whether the research applies to someone like you, and what is still unknown.
Several of these emerging topics will also be explored in greater depth during our Nutriamed Women's Wellness Series. Additional information, including upcoming topics and event dates, will be available on our website.
Selected References
1. U.S. Food and Drug Administration. FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease. May 16, 2025. Source
2. U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026. Source
3. U.S. Food and Drug Administration. FDA Approves Higher-Dose Semaglutide. March 19, 2026. Source
4. U.S. Food and Drug Administration. FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children. June 12, 2026. Source
5. U.S. Food and Drug Administration. FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar. August 25, 2026. Source
6. National Cancer Institute. Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the Horizon? April 23, 2025. Source
7. National Institutes of Health. Engineering Immune Cells Within the Body. July 15, 2025. Source
8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Updated 2026. Source
9. Reuters. FDA Panel Reviews Popular Unapproved Peptides Amid Questions About Evidence and Safety. June-July 2026. Source
10. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526. Source
11. U.S. Food and Drug Administration. Lynkuet (elinzanetant) approval information for moderate to severe vasomotor symptoms due to menopause. October 2025. Source
12. Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine. 2021;18:849-867. Source
13. Giblin K, et al. Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis: Rationale and Design of the TRIUMPH Registrational Clinical Trials. Diabetes, Obesity and Metabolism. 2026;28:83-93. Source
